{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:01:16Z","timestamp":1770742876456,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese medicine emergency special project of the State Administration of Traditional Chinese Medicine on novel coronavirus infection","award":["2023ZYLCYJ02-10"],"award-info":[{"award-number":["2023ZYLCYJ02-10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10823-8","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T09:06:55Z","timestamp":1743412015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and metabolomic analysis of the pneumonia compound formulation against community-acquired pneumonia: an observational controlled before-after clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meixia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"7","key":"10823_CR1","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with Community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10823_CR2","doi-asserted-by":"publisher","first-page":"ofab499","DOI":"10.1093\/ofid\/ofab499","volume":"8","author":"T Qin","year":"2021","unstructured":"Qin T, Zhou H, Ren H, Meng J, Du Y, Mahemut M, et al. Incidence, etiology, and environmental risk factors of Community-Acquired pneumonia requiring hospitalization in China: A 3-Year, prospective, Age-Stratified, multicenter Case-Control study. Open Forum Infect Dis. 2021;8(11):ofab499.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10823_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jiph.2022.07.008","volume":"15","author":"CY Wang","year":"2022","unstructured":"Wang CY, Chen CH, Tu CY, Chen WC, Kuo LK, Wang YT, et al. Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia. J Infect Public Health. 2022;15(9):961\u20135.","journal-title":"J Infect Public Health"},{"issue":"5","key":"10823_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5582\/bst.2021.01342","volume":"15","author":"L Shen","year":"2021","unstructured":"Shen L, Wang L, Liu C, Shi S, Takahashi T, Wang T. Community-acquired pneumonia: trends in and research on drug resistance and advances in new antibiotics. Biosci Trends. 2021;15(5):266\u201375.","journal-title":"Biosci Trends"},{"issue":"1","key":"10823_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/antibiotics13010098","volume":"13","author":"A Al-Tarawneh","year":"2024","unstructured":"Al-Tarawneh A, Ali T, Al-Taani GM. Public patterns and determinants of antibiotic Self-Medication and antibiotic knowledge in Southern Jordan. Antibiot (Basel). 2024;13(1):98.","journal-title":"Antibiot (Basel)"},{"issue":"11","key":"10823_CR6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/antibiotics12111621","volume":"12","author":"F Giovagnorio","year":"2023","unstructured":"Giovagnorio F, De Vito A, Madeddu G, Parisi SG, Geremia N. Resistance in Pseudomonas aeruginosa: A narrative review of antibiogram interpretation and emerging treatments. Antibiot (Basel). 2023;12(11):1621.","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"10823_CR7","doi-asserted-by":"publisher","first-page":"e082257","DOI":"10.1136\/bmjopen-2023-082257","volume":"14","author":"Y Sharma","year":"2024","unstructured":"Sharma Y, Sumanadasa S, Shahi R, Thompson C. Role of vitamin C in treatment of community-acquired pneumonia in adult patients requiring hospitalisation: a systematic review protocol. BMJ Open. 2024;14(3):e082257.","journal-title":"BMJ Open"},{"key":"10823_CR8","doi-asserted-by":"publisher","first-page":"923395","DOI":"10.3389\/fphar.2022.923395","volume":"13","author":"XW Zhang","year":"2022","unstructured":"Zhang XW, Xia RY, Gao JQ, Liu JJ, Xu DH, Li X, et al. Chinese patent medicine Shufeng Jiedu capsules as an adjuvant therapy for Community-Acquired pneumonia: A systematic review and Meta-Analysis of randomized clinical trials. Front Pharmacol. 2022;13:923395.","journal-title":"Front Pharmacol"},{"key":"10823_CR9","doi-asserted-by":"publisher","first-page":"106919","DOI":"10.1016\/j.phrs.2023.106919","volume":"196","author":"M Wang","year":"2023","unstructured":"Wang M, Liu H, Chen Y, Yu J, Lin J, Sun Z, et al. Guideline on treating community-acquired pneumonia with Chinese patent medicines. Pharmacol Res. 2023;196:106919.","journal-title":"Pharmacol Res"},{"issue":"1","key":"10823_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s13063-018-3005-9","volume":"19","author":"H Wang","year":"2018","unstructured":"Wang H, Li J, Yu X, Li SY. Integrated traditional Chinese and conventional medicine in treatment of severe community-acquired pneumonia: study protocol for a randomized placebo-controlled trial. Trials. 2018;19(1):620.","journal-title":"Trials"},{"issue":"12","key":"10823_CR11","first-page":"7458","volume":"36","author":"KQ Chai","year":"2021","unstructured":"Chai KQ, Huang FH, Li YP, Zhou Y, Chen YB, Hu X. Clinical study of traditional Chinese medicine against Corona virus disease 2019. China J Traditional Chin Med Pharm. 2021;36(12):7458\u201362.","journal-title":"China J Traditional Chin Med Pharm"},{"key":"10823_CR12","doi-asserted-by":"publisher","first-page":"1116131","DOI":"10.3389\/fimmu.2023.1116131","volume":"14","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Sharma L, Chang D. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review. Front Immunol. 2023;14:1116131.","journal-title":"Front Immunol"},{"issue":"4","key":"10823_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.idc.2004.07.004","volume":"18","author":"RG Wunderink","year":"2004","unstructured":"Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am. 2004;18(4):743\u2013vii.","journal-title":"Infect Dis Clin North Am"},{"issue":"1","key":"10823_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13054-018-2049-2","volume":"22","author":"P Ning","year":"2018","unstructured":"Ning P, Zheng Y, Luo Q, Liu X, Kang Y, Zhang Y, et al. Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity. Crit Care. 2018;22(1):130.","journal-title":"Crit Care"},{"key":"10823_CR15","doi-asserted-by":"publisher","first-page":"102556","DOI":"10.1016\/j.redox.2022.102556","volume":"58","author":"W Nan","year":"2022","unstructured":"Nan W, Xiong F, Zheng H, Li C, Lou C, Lei X, et al. Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia. Redox Biol. 2022;58:102556.","journal-title":"Redox Biol"},{"issue":"7","key":"10823_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00125-024-06153-0","volume":"67","author":"GS Taylor","year":"2024","unstructured":"Taylor GS, Smith K, Scragg J, McDonald TJ, Shaw JA, West DJ, et al. The metabolome as a diagnostic for maximal aerobic capacity during exercise in type 1 diabetes. Diabetologia. 2024;67(7):1413\u201328.","journal-title":"Diabetologia"},{"key":"10823_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13020-019-0229-x","volume":"14","author":"L Lin","year":"2019","unstructured":"Lin L, Yan H, Chen J, Xie H, Peng L, Xie T, et al. Application of metabolomics in viral pneumonia treatment with traditional Chinese medicine. Chin Med. 2019;14:8.","journal-title":"Chin Med"},{"key":"10823_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2147\/DDDT.S446336","volume":"18","author":"T Wen","year":"2024","unstructured":"Wen T, Liu X, Pang T, Li M, Jiao G, Fan X, et al. The efficacy of Chaihu-Guizhi-Ganjiang Decoction on chronic Non-Atrophic gastritis with gallbladder heat and spleen cold syndrome and its metabolomic analysis: an observational controlled Before-After clinical trial. Drug Des Devel Ther. 2024;18:881\u201397.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10823_CR19","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/crj.12674","volume":"12","author":"B Cao","year":"2018","unstructured":"Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese thoracic society, Chinese medical association. Clin Respir J. 2018;12(4):1320\u201360.","journal-title":"Clin Respir J"},{"key":"10823_CR20","first-page":"74","volume-title":"The Sanford guide to antimicrobial therapy 2020 (50th edition) [M]","author":"DN Gilbert","year":"2021","unstructured":"Gilbert DN, Chambers HF, Saag MS, et al. The Sanford guide to antimicrobial therapy 2020 (50th edition) [M]. Beijing, China: China Union Medical College; 2021. p. 74."},{"key":"10823_CR21","doi-asserted-by":"publisher","first-page":"155960","DOI":"10.1016\/j.phymed.2024.155960","volume":"134","author":"L Lin","year":"2024","unstructured":"Lin L, Xiao J, Wu L, Fan F, Feng W, Wei J, et al. Efficacy and safety of Kegan Liyan oral liquid for patients with acute pharyngitis: A randomized, double-blinded, placebo-controlled, multi-center trial. Phytomedicine. 2024;134:155960.","journal-title":"Phytomedicine"},{"key":"10823_CR22","doi-asserted-by":"publisher","first-page":"8682612","DOI":"10.1155\/2022\/8682612","volume":"2022","author":"X Li","year":"2022","unstructured":"Li X, Li X, Gong M, Li C, Li J, Zhou C, et al. Modified Xiaochaihu Decoction combined with Mirtazapine in the treatment of persistent depression: A pilot randomized controlled trial. Contrast Media Mol Imaging. 2022;2022:8682612.","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"10823_CR23","doi-asserted-by":"publisher","first-page":"33037","DOI":"10.12788\/jhm.3106","volume":"14","author":"K Vadamalai","year":"2019","unstructured":"Vadamalai K, Sanche-Tejera D, Bress J, Mustafa SS. Screening for humoral immunodeficiency in patients with Community-Acquired pneumonia. J Hosp Med. 2019;14(1):33037.","journal-title":"J Hosp Med"},{"issue":"3","key":"10823_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1021\/ac051437y","volume":"78","author":"CA Smith","year":"2006","unstructured":"Smith CA, Want EJ, O\u2019Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006;78(3):779\u201387.","journal-title":"Anal Chem"},{"issue":"1","key":"10823_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12859-017-1579-y","volume":"18","author":"B Wen","year":"2017","unstructured":"Wen B, Mei Z, Zeng C, Liu S. MetaX: a flexible and comprehensive software for processing metabolomics data. BMC Bioinformatics. 2017;18(1):183.","journal-title":"BMC Bioinformatics"},{"key":"10823_CR26","doi-asserted-by":"publisher","first-page":"134360","DOI":"10.1016\/j.jhazmat.2024.134360","volume":"471","author":"A Liu","year":"2024","unstructured":"Liu A, Li Y, Li L, Chen K, Tan M, Zou F, et al. Bile acid metabolism is altered in learning and memory impairment induced by chronic lead exposure. J Hazard Mater. 2024;471:134360.","journal-title":"J Hazard Mater"},{"issue":"1","key":"10823_CR27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12879-023-08283-z","volume":"23","author":"X Tang","year":"2023","unstructured":"Tang X, Wang N, Liu G, Tan H, Li AM, Gao YQ, et al. Psittacosis caused severe community-acquired pneumonia accompanied by acute hypoxic respiratory failure: a multicenter retrospective cohort study from China. BMC Infect Dis. 2023;23(1):532.","journal-title":"BMC Infect Dis"},{"key":"10823_CR28","doi-asserted-by":"publisher","first-page":"1027901","DOI":"10.3389\/fphar.2022.1027901","volume":"13","author":"M Liang","year":"2022","unstructured":"Liang M, Hu L, Luo N, Lv H, Chen Z, Mo J, et al. Effects of Juhongtanke oral solution on alleviating the symptoms of community-acquired pneumonia: A multicenter, prospective, randomized controlled trial. Front Pharmacol. 2022;13:1027901.","journal-title":"Front Pharmacol"},{"issue":"1","key":"10823_CR29","doi-asserted-by":"publisher","first-page":"e000152","DOI":"10.1136\/bmjresp-2016-000152","volume":"3","author":"MC de la Torre","year":"2016","unstructured":"de la Torre MC, Toran P, Serra-Prat M, Palomera E, Guell E, Vendrell E, et al. Serum levels of Immunoglobulins and severity of community-acquired pneumonia. BMJ Open Respir Res. 2016;3(1):e000152.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10823_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s13054-023-04719-9","volume":"27","author":"M Singer","year":"2023","unstructured":"Singer M, Torres A, Heinz CC, Weissmuller S, Staus A, Kistner S, et al. The Immunomodulating activity of Trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial. Crit Care. 2023;27(1):436.","journal-title":"Crit Care"},{"key":"10823_CR31","doi-asserted-by":"publisher","first-page":"155397","DOI":"10.1016\/j.phymed.2024.155397","volume":"128","author":"A Zhao","year":"2024","unstructured":"Zhao A, Guo C, Wang L, Chen S, Xu Q, Cheng J, et al. Xiebai San alleviates acute lung injury by inhibiting the phosphorylation of the ERK\/Stat3 pathway and regulating multiple metabolisms. Phytomedicine. 2024;128:155397.","journal-title":"Phytomedicine"},{"issue":"2","key":"10823_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jtcme.2022.09.001","volume":"13","author":"X Cui","year":"2023","unstructured":"Cui X, Guo Y, Liu Q. Qingfei Jiedu granules fight influenza by regulating inflammation, immunity, metabolism, and gut microbiota. J Tradit Complement Med. 2023;13(2):170\u201382.","journal-title":"J Tradit Complement Med"},{"key":"10823_CR33","doi-asserted-by":"publisher","first-page":"105701","DOI":"10.1016\/j.neuint.2024.105701","volume":"175","author":"C Sarkar","year":"2024","unstructured":"Sarkar C, Lipinski MM. Glycerophospholipid dysregulation after traumatic brain injury. Neurochem Int. 2024;175:105701.","journal-title":"Neurochem Int"},{"issue":"1","key":"10823_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12931-024-02669-6","volume":"25","author":"J Li","year":"2024","unstructured":"Li J, Wang Y, Zhao W, Yang T, Zhang Q, Yang H, et al. Multi-omics analysis reveals overactive inflammation and dysregulated metabolism in severe community-acquired pneumonia patients. Respir Res. 2024;25(1):45.","journal-title":"Respir Res"},{"issue":"1","key":"10823_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/22221751.2022.2036582","volume":"11","author":"J Li","year":"2022","unstructured":"Li J, Luu LDW, Wang X, Cui X, Huang X, Fu J, et al. Metabolomic analysis reveals potential biomarkers and the underlying pathogenesis involved in Mycoplasma pneumoniae pneumonia. Emerg Microbes Infect. 2022;11(1):593\u2013605.","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10823_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12967-019-2112-z","volume":"17","author":"H Arshad","year":"2019","unstructured":"Arshad H, Alfonso JCL, Franke R, Michaelis K, Araujo L, Habib A, et al. Decreased plasma phospholipid concentrations and increased acid Sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia. J Transl Med. 2019;17(1):365.","journal-title":"J Transl Med"},{"issue":"12","key":"10823_CR37","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.7150\/ijbs.72450","volume":"18","author":"M Xue","year":"2022","unstructured":"Xue M, Zhang T, Cheng ZJ, Guo B, Zeng Y, Lin R, et al. Effect of a functional phospholipid Metabolome-Protein association pathway on the mechanism of COVID-19 disease progression. Int J Biol Sci. 2022;18(12):4618\u201328.","journal-title":"Int J Biol Sci"},{"key":"10823_CR38","doi-asserted-by":"publisher","first-page":"730022","DOI":"10.3389\/fimmu.2021.730022","volume":"12","author":"J Ji","year":"2021","unstructured":"Ji J, Sun L, Luo Z, Zhang Y, Xianzheng W, Liao Y, et al. Potential therapeutic applications of pulmonary surfactant lipids in the host defence against respiratory viral infections. Front Immunol. 2021;12:730022.","journal-title":"Front Immunol"},{"issue":"9","key":"10823_CR39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/17512433.2023.2238602","volume":"16","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ma Z, Wang Y, Feng X, An Z. Phosphatidylinositol 3 kinase inhibitor-related pneumonitis: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2023;16(9):855\u201363.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10823_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13054-023-04552-0","volume":"27","author":"Y Chang","year":"2023","unstructured":"Chang Y, Yoo HJ, Kim SJ, Lee K, Lim CM, Hong SB, et al. A targeted metabolomics approach for sepsis-induced ARDS and its subphenotypes. Crit Care. 2023;27(1):263.","journal-title":"Crit Care"},{"key":"10823_CR41","doi-asserted-by":"publisher","first-page":"110277","DOI":"10.1016\/j.mehy.2020.110277","volume":"144","author":"WB Bollag","year":"2020","unstructured":"Bollag WB, Gonzales JN. Phosphatidylglycerol and surfactant: A potential treatment for COVID-19? Med Hypotheses. 2020;144:110277.","journal-title":"Med Hypotheses"},{"issue":"1","key":"10823_CR42","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/imr.13207","volume":"317","author":"M Numata","year":"2023","unstructured":"Numata M, Kandasamy P, Voelker DR. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. Immunol Rev. 2023;317(1):166\u201386.","journal-title":"Immunol Rev"},{"issue":"15","key":"10823_CR43","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3390\/ijms20153716","volume":"20","author":"H Li","year":"2019","unstructured":"Li H, Wang B, Yang H, Wang Y, Xing L, Chen W, et al. Furosine posed toxic effects on primary Sertoli cells through regulating Cep55\/NF-\u03baB\/PI3K\/Akt\/FOX01\/TNF-\u03b1 pathway. Int J Mol Sci. 2019;20(15):3716.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10823-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T12:24:49Z","timestamp":1743510289000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10823-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10823"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10823-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Ethics Committee of Tongde Hospital of Zhejiang Province (Approval No. 2023-045(K)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Our study adheres to Consort guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consort statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"441"}}